Antimicrobial Dosing in Obese Patients
Author(s) -
Rebecca Wurtz,
Gail S. Itokazu,
Keith A. Rodvold
Publication year - 1997
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/514505
Subject(s) - dosing , pharmacokinetics , medicine , antimicrobial , antibiotics , body weight , pharmacology , microbiology and biotechnology , biology
Although the dose of some drugs is commonly adjusted for weight, weight-related dosage adjustments are rarely made for most antimicrobials. We reviewed the English-language literature on antimicrobial pharmacokinetics and dosing in obesity. Although there are many potential pharmacokinetic consequences of obesity, the actual effect on the pharmacokinetics and clinical efficacy of most antimicrobials is unknown. Since approximately 30% of adipose is water, an empirical approach is use of the Devine formula to calculate ideal body weight (IBW), to which is added a dosing weight correction factor (DWCF) of 0.3 times the difference between actual body weight (ABW) and IBW (IBW + 0.3 x [ABW-IBW]) to arrive at a weight on which to base dosage of hydrophilic antibiotics. No studies confirm this approach for beta-lactam drugs. Clinical studies suggest a DWCF of approximately 0.40 for aminoglycosides and 0.45 for quinolones. Final dosage adjustments for antimicrobials with a narrow toxic-therapeutic window should be based on serum concentrations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom